Mark Rubinstein to Melanoma
This is a "connection" page, showing publications Mark Rubinstein has written about Melanoma.
Connection Strength
1.230
-
Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. 2015 May; 64(5):539-49.
Score: 0.362
-
Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. 2012 Apr; 214(4):700-7; discussion 707-8.
Score: 0.294
-
B cells imprint adoptively transferred CD8+ T cells with enhanced tumor immunity. J Immunother Cancer. 2022 01; 10(1).
Score: 0.146
-
Modeling ex vivo tumor-infiltrating lymphocyte expansion from established solid malignancies. Oncoimmunology. 2021; 10(1):1959101.
Score: 0.142
-
Lack of p53 Augments Antitumor Functions in Cytolytic T Cells. Cancer Res. 2016 09 15; 76(18):5229-5240.
Score: 0.100
-
The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. 2015 Feb 15; 194(4):1737-47.
Score: 0.090
-
Interleukin-15/interleukin-15R alpha complexes promote destruction of established tumors by reviving tumor-resident CD8+ T cells. Cancer Res. 2008 Apr 15; 68(8):2972-83.
Score: 0.056
-
CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003 Mar 01; 170(5):2582-9.
Score: 0.040